Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy...

Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate
Strategy and Milestones

SOUTH SAN FRANCISCO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Anesiva,
Inc. (Nasdaq: ANSV) announced that it will hold a conference call and webcast
on Wednesday, September 3, 2008 at 11:30 am Eastern time (8:30 am Pacific
time). During the call, Anesiva management will update its corporate strategy
and product development milestones, following a comprehensive review of the
company's business.
Interested parties can listen to the live conference call by dialing
866-616-3642 (international dial: 706-643-3817) or by logging on to
http://www.anesiva.com and going to the Investor Information page. For those
unable to participate via the Internet, a replay will be available for seven
days after the call by dialing 800-642-1687 (international dial: 706-645-9291)
and giving the following pass code: 62641912. The webcast will be available
until the company's next quarterly financial results conference call.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a commercial-stage specialty pharmaceutical company that
seeks to be a leader in the development and commercialization of novel
pharmaceutical products for pain management. The company's first commercial
product, Zingo(TM), is available in the U.S. for the reduction of pain
associated with peripheral venous access procedures in children ages three to
18. For full Zingo prescribing information and other information, visit
http://www.zingo.com. An application is under FDA review to expand the Zingo
label indication to include adults.
The next product in Anesiva's pipeline, Adlea(TM), is currently being
evaluated in multiple clinical trials for the management of acute pain
following orthopedic surgeries. Adlea has been shown in Phase 2 trials to
reduce pain after only a single administration for weeks to months in multiple
indications for site-specific, acute and chronic, moderate-to-severe pain.
Anesiva is based in South San Francisco, CA. For more information about
Anesiva's leadership in the development and commercialization of products for
pain management, and an overview of the clinical challenges being addressed by
its product candidates, go to http://www.anesiva.com.
SOURCE Anesiva, Inc.

Carol DeGuzman, Senior Director, Investor Relations, +1-650-246-6898,
investors@anesiva.com; or media, Katie Compa of WeissComm Partners,
+1-415-946-1078, kcompa@wcpglobal.com, for Anesiva, Inc.